Medical Management of Primary Hyperparathyroidism with Concommitant Multiple Myeloma

Fanari, Zaher; Kadikoy, Hüseyin; Haque, Waqar; Pacha, Omar; Abdellatif, Abdul

doi:10.2169/internalmedicine.49.2705

Cited by 12 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Medical management has been successful in previous cases with hypercalcemia due to primary hyperparathyroidism accompanying multiple myeloma [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

A case of hypercalcemia with double pathology

Abdalla

Bachuwa

Hadidi

2017

Journal of Community Hospital Internal Medicine Perspectives

View full text Add to dashboard Cite

Hypercalcemia has many causes including primary hyperparathyroidism, malignancy, and other rare etiologies. In most of the cases, hypercalcemia is secondary to one etiology. In this case, we are reporting hypercalcemia with two causes. The initial workup showed primary hyperparathyroidism due to parathyroid adenoma. But because all features were not fully explained by primary hyperparathyroidism, further work-up revealed multiple myeloma. This case represents coexistence of two different diseases, which was rarely reported in the literature previously. Usually, the co-diagnosis was made subsequently after failure to correct hypercalcemia. In our case, both diagnoses were established at the same time of the patient’s presentation as of high suspicion. Establishing the diagnosis early will aid in the initiation of treatment in a timely fashion.

show abstract

“…Medical management has been successful in previous cases with hypercalcemia due to primary hyperparathyroidism accompanying multiple myeloma [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

A case of hypercalcemia with double pathology

Abdalla

Bachuwa

Hadidi

2017

Journal of Community Hospital Internal Medicine Perspectives

View full text Add to dashboard Cite

show abstract

“…106 Hypocalcemia occurred and resolved with calcium and calcitriol supplementation. The patient discontinued all drugs and died.…”

Section: Cinacalcet In Unusual Phpt Casesmentioning

confidence: 99%

Medical Management of Primary Hyperparathyroidism

Marcocci

Khan

2015

The Parathyroids

View full text Add to dashboard Cite

“…Hypercalcemia recurred after cinacalcet withdrawal and the patient underwent successful PTx. Cinacalcet (30 mg twice daily), in association with pamidronate and other calcium-lowering strategies, has proven to be useful in controlling hypercalcemia in a woman with PHPT associated with advanced myeloma [35]. Hypocalcemia developed during treatment and required calcium and calcitriol administration.…”

Section: Reviewmentioning

confidence: 99%

Cinacalcet in the management of primary hyperparathyroidism

Cetani¹,

Marcocci²

2012

Expert Review of Endocrinology & Metabolism

View full text Add to dashboard Cite

Parathyroidectomy is currently the only curative treatment for primary hyperparathyroidism (PHPT). There are few alternative treatment options in patients who are ineligible for, or unwilling to undergo, surgery and those in whom parathyroidectomy has failed. Current options include the recently approved drug cinacalcet. Cinacalcet is an allosteric modulator of the calciumsensing receptor, acting to sensitize this receptor to extracellular calcium. Cinacalcet has been found to be effective in reducing or normalizing serum calcium levels in several groups of PHPT patients, including those with mild-to-moderate PHPT, intractable disease, parathyroid carcinoma and multiple endocrine neoplasia Type 1. Cinacalcet slightly reduces parathyroid hormone levels and has no effect on bone mineral density. Cinacalcet is well tolerated when used at low doses, but side effects are not uncommon when relatively high doses are needed to control hypercalcemia. The current evidence indicates that cinacalcet may be of benefit in a wide spectrum of PHPT severities, offering a novel therapeutic option for the control of hypercalcemia in PHPT patients who are not able to undergo parathyroidectomy. It is presently unknown how much of the biochemical benefit of cinacalcet treatment translates into a clinical benefit, particularly in patients with mild-to-moderate hypercalcemia. Moreover, there are no data as to whether long-term treatment with cinacalcet can prevent the complications of PHPT. Keywords: calcium-sensing receptor • hypercalcemia • parathyroid carcinoma • persistent primary hyperparathyroidism Cinacalcet in the management of primary hyperparathyroidism Expert Rev.

show abstract

Medical Management of Primary Hyperparathyroidism with Concommitant Multiple Myeloma

Abstract: Primary hyperparathyroidism (PHPT) and multiple myeloma (MM)

Cited by 12 publications

References 20 publications

A case of hypercalcemia with double pathology

A case of hypercalcemia with double pathology

Medical Management of Primary Hyperparathyroidism

Cinacalcet in the management of primary hyperparathyroidism

Contact Info

Product

Resources

About